Forentis Partners has announced that Forentis Fund, a $50 million biotechnological special purpose venture fund, is committed to providing $7 million. $5 million in funding to Blueprint Bio, Inc. , the first of the company’s target portfolio companies to receive a commitment to finance
‘Our strategy at Forentis is to provide capital resources and support to our group of selected target portfolio companies,’ said Jay Goth, Forentis Managing Partner. ‘This capital infusion will allow Blueprint to further develop its portfolio of intellectual property assets and to fund additional discoveries. As a marketing engine for our ecosystem, Blueprint will be the first in the line of funding. ”
Blueprint Bio was founded in 2015 with the aim of generating and transforming intellectual property into commercial and social value, complying with the personalized medicine model. By identifying, protecting and offering new biological discoveries to existing clinical, pharmaceutical and diagnostic companies, Blueprint is creating a validated marketplace for biomarker signatures in personalized medicines.
In order to de-risk and accelerate their discovery of biomarkers, Blueprint is actively collaborating with researchers and companies that generate biologic patient data from omics devices such as mass spectrometers and gene sequencing machines, among other assay methods, at an unprecedented rate. Blueprint is based in California and has additional offices at the University of Pennsylvania and the Mayo Clinic.
The company is a co-founder of BluePen Biomarkers, a recently announced biomarker research and discovery initiative. BluePen is developing a comprehensive biomarker measurement and discovery pipeline for the acceleration of personalized medicine. The company was recently published in Future Science Magazine
‘Blueprint has been designed to become a marketing engine for precision medicine solutions,’ said Matthew Nunez, CEO of both Blueprint Bio and BluePen Biomarkers. ‘Through BluePen Biomarkers, we will have access to a wide range of new biological discoveries through our unique multi-omics platform. Our job at Blueprint is to bring these discoveries to the market as quickly and efficiently as possible. We have a number of projects already underway ”
Blueprint Bio has filed patent applications in a variety of drug response solutions and oncology-focused diagnostics, further building investor value and advancing its mission to help patients through the best-in-class biomarker-based products through its marketing pipeline.
On the Forentis Fund
The Forentis Fund is committed to saving lives and returning reason to the pharmaceutical and diagnostic industries. The Fund is strategically located at the Murrieta Innovation Center in Murrieta, California, providing access to leading biotechnological research centers in Los Angeles, San Diego and Orange County. The Fund is within easy driving distance from UCSD, UCR, UCI, UCLA and USC. The Forentis Fund is only available to accredited investors. More information about the Fund and its investment approach can be found at www. Forentis: Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Blueprint%20Bio/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
